High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma.
Fredlund, Erik LU ; Ringnér, Markus LU
; Maris, John M
and Påhlman, Sven
LU
(2008)
In Proceedings of the National Academy of Sciences
105(37).
p.14094-14099
- Abstract
- The childhood cancer neuroblastoma arises in the developing sympathetic nervous system and is a genotypically and phenotypically heterogeneous disease. Prognostic markers of poor survival probability include amplification of the MYCN oncogene and an undifferentiated morphology. Whereas these features discriminate high- from low-risk patients with precision, identification of poor outcome low- and intermediate-risk patients is more challenging. In this study, we analyze two large neuroblastoma microarray datasets using a priori-defined gene expression signatures. We show that differential overexpression of Myc transcriptional targets and low expression of genes involved in sympathetic neuronal differentiation predicts relapse and death from... (More)
- The childhood cancer neuroblastoma arises in the developing sympathetic nervous system and is a genotypically and phenotypically heterogeneous disease. Prognostic markers of poor survival probability include amplification of the MYCN oncogene and an undifferentiated morphology. Whereas these features discriminate high- from low-risk patients with precision, identification of poor outcome low- and intermediate-risk patients is more challenging. In this study, we analyze two large neuroblastoma microarray datasets using a priori-defined gene expression signatures. We show that differential overexpression of Myc transcriptional targets and low expression of genes involved in sympathetic neuronal differentiation predicts relapse and death from disease. This was evident not only for high-risk patients but was also robust in identifying groups of poor prognosis patients who were otherwise judged to be at low- or intermediate-risk for adverse outcome. These data suggest that pathway-specific gene expression profiling might be useful in the clinic to adjust treatment strategies for children with neuroblastoma. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1243221
- author
- Fredlund, Erik
LU
; Ringnér, Markus
LU
; Maris, John M
and Påhlman, Sven
LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Proceedings of the National Academy of Sciences
- volume
- 105
- issue
- 37
- pages
- 14094 - 14099
- publisher
- National Academy of Sciences
- external identifiers
-
- wos:000259438500074
- pmid:18780787
- scopus:52949154642
- pmid:18780787
- ISSN
- 1091-6490
- DOI
- 10.1073/pnas.0804455105
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Oncology, MV (013035000), Molecular Medicine (013031200)
- id
- aae27d0d-f577-4c9d-aa1b-159be1ffabb4 (old id 1243221)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18780787?dopt=Abstract
- date added to LUP
- 2016-04-04 07:23:48
- date last changed
- 2022-03-23 01:05:01
@article{aae27d0d-f577-4c9d-aa1b-159be1ffabb4,
abstract = {{The childhood cancer neuroblastoma arises in the developing sympathetic nervous system and is a genotypically and phenotypically heterogeneous disease. Prognostic markers of poor survival probability include amplification of the MYCN oncogene and an undifferentiated morphology. Whereas these features discriminate high- from low-risk patients with precision, identification of poor outcome low- and intermediate-risk patients is more challenging. In this study, we analyze two large neuroblastoma microarray datasets using a priori-defined gene expression signatures. We show that differential overexpression of Myc transcriptional targets and low expression of genes involved in sympathetic neuronal differentiation predicts relapse and death from disease. This was evident not only for high-risk patients but was also robust in identifying groups of poor prognosis patients who were otherwise judged to be at low- or intermediate-risk for adverse outcome. These data suggest that pathway-specific gene expression profiling might be useful in the clinic to adjust treatment strategies for children with neuroblastoma.}},
author = {{Fredlund, Erik and Ringnér, Markus and Maris, John M and Påhlman, Sven}},
issn = {{1091-6490}},
language = {{eng}},
number = {{37}},
pages = {{14094--14099}},
publisher = {{National Academy of Sciences}},
series = {{Proceedings of the National Academy of Sciences}},
title = {{High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma.}},
url = {{http://dx.doi.org/10.1073/pnas.0804455105}},
doi = {{10.1073/pnas.0804455105}},
volume = {{105}},
year = {{2008}},
}